Yes, Reclast is a bisphosphonate. Its active ingredient is zoledronic acid, and the FDA classifies it as a bisphosphonate that acts primarily on bone. It is one of the most potent drugs in this class, delivered as a single intravenous infusion once a year rather than taken as a daily or weekly pill like older bisphosphonates such as alendronate (Fosamax).
How Reclast Works on Bone
Like all bisphosphonates, Reclast slows bone loss by targeting the cells responsible for breaking down bone tissue. These cells, called osteoclasts, are a normal part of bone remodeling, but in conditions like osteoporosis they outpace the cells that build new bone. Zoledronic acid binds to bone mineral and, when osteoclasts absorb it during remodeling, it blocks a key enzyme inside those cells called farnesyl pyrophosphate synthase. This disrupts the osteoclasts’ ability to function and survive, which shifts the balance back toward bone preservation.
What makes Reclast distinct from oral bisphosphonates is its especially high affinity for bone mineral. Once deposited in the skeleton, it stays active for a long time, which is why a single 5 mg infusion provides a full year of protection.
What Reclast Is Approved to Treat
The FDA has approved Reclast for several bone-related conditions:
- Postmenopausal osteoporosis: both treatment and prevention
- Osteoporosis in men: to increase bone mass
- Glucocorticoid-induced osteoporosis: for people taking the equivalent of 7.5 mg or more of prednisone daily who are expected to stay on steroids for at least 12 months
- Paget’s disease of bone: a condition where bone remodeling becomes chaotic, leading to enlarged or misshapen bones
How the Infusion Works
Reclast is given through an IV, typically in a doctor’s office or infusion center. The infusion takes at least 15 minutes and delivers a 5 mg dose. For osteoporosis, this happens once a year. You’ll need to drink at least two glasses of water or another fluid in the hours before your appointment, because adequate hydration helps protect your kidneys during the infusion.
The once-yearly schedule is a major practical advantage. Oral bisphosphonates require careful timing: you typically have to take them first thing in the morning on an empty stomach, stay upright for 30 to 60 minutes, and avoid eating or drinking anything else during that window. Many people struggle to follow these instructions consistently. With Reclast, adherence isn’t an issue because a healthcare provider administers the dose directly.
How It Compares to Other Bisphosphonates
Registry-based research comparing zoledronic acid to alendronate found that Reclast performs at least as well for fracture prevention. In one large study, zoledronic acid matched denosumab (Prolia) in overall fracture risk reduction, while alendronate and ibandronate were associated with higher fracture rates than denosumab for vertebral and overall fractures. For patients who want strong fracture protection with minimal day-to-day hassle, Reclast sits at the top of the bisphosphonate class.
Post-Infusion Side Effects
The most common reaction after a Reclast infusion is a flu-like response: fever, muscle aches, headache, and joint pain. Most patients who experience this notice symptoms within the first three days. These effects are self-limiting and typically resolve within 24 to 48 hours, though in some cases they can appear up to two weeks after the infusion. The reaction tends to be strongest after the first infusion and milder with subsequent yearly doses. Over-the-counter pain relievers like acetaminophen or ibuprofen can help manage the discomfort.
Rare but Serious Risks
Two uncommon complications are associated with bisphosphonates, including Reclast: osteonecrosis of the jaw and atypical femur fractures.
Osteonecrosis of the jaw is a condition where a patch of jawbone loses its blood supply and the overlying tissue breaks down, leaving exposed bone that doesn’t heal. Data from cancer patients receiving zoledronic acid (often at higher and more frequent doses than those used for osteoporosis) showed rates of about 1% after one year, 2% after two years, and 3% after three years. Rates were highest in people with multiple myeloma (4.3%) and lowest in those with breast cancer that had spread to bone (2.4%). In osteoporosis patients receiving once-yearly dosing, the risk is considerably lower, but dental work, particularly tooth extractions, can increase it.
Atypical femur fractures are stress fractures in the thigh bone that occur with minimal or no trauma. They are linked to long-term bisphosphonate use, which is one reason clinicians now recommend periodic breaks from treatment.
Kidney Function Requirements
Reclast is processed through the kidneys, and it is contraindicated in people with a creatinine clearance below 35 mL/min or any signs of acute kidney problems. Your kidney function should be checked before each infusion. Staying well hydrated before and after the infusion is particularly important if you take diuretics, because dehydration increases the risk of kidney stress.
How Long Treatment Typically Lasts
Bisphosphonate therapy isn’t meant to continue indefinitely. Because zoledronic acid binds tightly to bone and remains active long after the last infusion, many patients eventually take a “drug holiday,” a planned pause from treatment. Current guidelines base the duration of treatment on fracture risk:
- Mild fracture risk: 3 to 5 years of treatment, then stop until bone density drops significantly or a fracture occurs
- Moderate fracture risk: 5 to 10 years of treatment, followed by a 3- to 5-year break
- High fracture risk (prior fractures, steroid use, very low bone density): up to 10 years of treatment, with a shorter holiday of 1 to 2 years
Because zoledronic acid has the highest skeletal affinity of the commonly used bisphosphonates, its protective effects linger longer after stopping. Experts suggest reassessing bone density 2 to 3 years into a drug holiday for Reclast, compared to just 1 year for risedronate. This prolonged residual activity is part of what makes the once-yearly dosing possible in the first place.